Seattle, WA
Sound Pharmaceuticals, a pioneer in the development of novel drug treatments for inner ear disease, announces the hiring of two senior executives. Paul Hoskins, Senior Director of Clinical Operations and G. Michael Wall, PhD, Senior Director of Pharmaceutical Development joined the company this past month. Read More
Seattle, WA
Sound Pharmaceuticals, a pioneer in the development of novel drug treatments for inner ear disease, announced today that Jonathan Kil, MD, Co-Founder and Chief Medical Officer, is a co-author on two publications from the Department of Defense’s Hearing Center of Excellence (HCE). The HCE is focused on the prevention, diagnosis, mitigation, treatment, and rehabilitation of hearing loss. HCE is congressionally directed to partner with the Department of Veterans Affairs (VA), and other organizations that support the study of auditory injury. The papers are part of a series of new guidance documents from the HCE published in the September issue of Otology & Neurotology, a leading otolaryngology journal. Read More
Sound Pharmaceuticals (SPI) has submitted a scientific abstract for presentation at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting in Orlando FL.
Read More
SEATTLE, Nov. 28, 2012 /PRNewswire/
Sound Pharmaceuticals, Inc. is honored to have Bruce A. Beutler, a recipient of the 2011 Nobel Prize in Physiology or Medicine for his discoveries involving the activation of innate immunity, join the company as a scientific advisor. Dr. Beutler is currently the Director of the Center for the Genetics of Host Defense at the University of Texas Southwestern Medical Center. In addition, he has identified and characterized COMT2, a genetic mutation that leads to human deafness. “He is an expert in the molecular pathways and biology that are at the heart of our science, and is a tremendous addition to our Scientific Advisory Board,” said Jonathan Kil, MD, Chief Medical Officer. SPI has developed an orally delivered small molecule (SPI-1005) that is currently in mid-stage or Ph-II clinical trials for the prevention and treatment of noise induced hearing loss and chemotherapy induced ototoxicity and tinnitus. SPI found that the enzyme glutathione peroxidase 1 (GPx1) is diminished in several critical cells and tissues in the cochlea of mammals immediately following noise exposure. SPI-1005 treatment increases the expression of GPx1 and is thought to allow these affected cells and tissues to repair themselves, thus restoring auditory function and preventing the irreversible loss of auditory hair cells and supporting cells. SPI is also developing a locally delivered drug for regenerating cells within the inner ear of mammals as a means to restore auditory function to the severely hearing impaired or deaf. By inhibiting p27Kip1, a cyclin dependent kinase inhibitor or CKI, supporting cell and auditory hair cell regeneration is stimulated in adult mice and Guinea pigs that were previously exposed to intense noise or ototoxic drugs. This novel proliferative and regenerative ability is absent in adult mammals, resulting in permanent and often progressive sensorineural hearing loss. This novel CKI technology could be applied to other neurodegenerative diseases. Sound Pharmaceuticals, Inc. is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please visit https://soundpharma.comEric Lynch, PhD, President, Sound Pharmaceuticals, Inc. 4010 Stone Way N Suite 120, Seattle WA 98103 Office: 206-634-2559 elynch@soundpharma.com
